Cargando…

Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects

BACKGROUND: Increased plasma plasminogen activator inhibitor-1 (PAI-1) activity and decreased tissue plasminogen activator (tPA) activity could be considered a true component of the metabolic syndrome (MetS) associated with an increased risk of developing cardiovascular diseases (CVD) and fibrinolyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Hamodi, Zaid, Ismail, Ikram S, Saif-Ali, Riyadh, Ahmed, Khaled A, Muniandy, Sekaran
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064636/
https://www.ncbi.nlm.nih.gov/pubmed/21414238
http://dx.doi.org/10.1186/1475-2840-10-23
_version_ 1782200903782105088
author Al-Hamodi, Zaid
Ismail, Ikram S
Saif-Ali, Riyadh
Ahmed, Khaled A
Muniandy, Sekaran
author_facet Al-Hamodi, Zaid
Ismail, Ikram S
Saif-Ali, Riyadh
Ahmed, Khaled A
Muniandy, Sekaran
author_sort Al-Hamodi, Zaid
collection PubMed
description BACKGROUND: Increased plasma plasminogen activator inhibitor-1 (PAI-1) activity and decreased tissue plasminogen activator (tPA) activity could be considered a true component of the metabolic syndrome (MetS) associated with an increased risk of developing cardiovascular diseases (CVD) and fibrinolytic abnormalities. The aim of this study was to investigate the association of tPA and its inhibitor PAI-1 with type 2 diabetes (T2D) and MetS and interrelationship between PAI-1and tPA activities and antigens in Malaysian T2D and normal subjects. METHODS: The plasma activities and antigens of PAI-1 and tPA and the levels of the tPA/PAI-1 complex as well as serum insulin, parameter of the coronary risk panel and plasma glucose at fasting state were studied in 303 T2D subjects (227 with MetS and 76 without MetS), 131 normal non-diabetic non-metabolic subjects and 101 non-diabetic MetS subjects. RESULTS: The PAI-1 activity was higher in subjects with T2D with MetS (P = 9.8 × 10(-19)) and non-diabetic subjects with MetS (P = 3.0 × 10(-15)), whereas the tPA activity was lower in T2D with MetS (P = 0.003) as compare to normal subjects. Plasma tPA antigen levels were higher in subjects with T2D with MetS (P = 8.9 × 10(-24)), T2D without MetS (P = 1.3 × 10(-13)) and non-diabetic MetS subjects (P = 0.002). The activity and antigen of PAI-1 in normal subjects were related to insulin resistance (P = 2.2 × 10(-4); 0.007). Additionally, the PAI-1 activity was associated with an increased waist circumference (P = 2.2 × 10(-4)) and decreased HDL-c (P = 0.005), whereas the tPA activity was associated with decreased FBG (P = 0.028). The highest correlation was between PAI-1 activity and its antigen (R(2 )= 0.695, P = 1.1 × 10(-36)) in diabetic subjects. The tPA activity negatively correlated with its antigen (R(2 )= -0.444, P = 7.7 × 10(-13)) in normal subjects and with the PAI-1 activity and antigen (R(2 )= -0.319, P = 9.9 × 10(-12); R2 = -0.228, P = 3.4 × 10(-6)) in diabetic subjects. CONCLUSIONS: PAI-1 and tPA activities and antigens were associated with diabetes and MetS parameters in Malaysian subjects.
format Text
id pubmed-3064636
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30646362011-03-26 Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects Al-Hamodi, Zaid Ismail, Ikram S Saif-Ali, Riyadh Ahmed, Khaled A Muniandy, Sekaran Cardiovasc Diabetol Original Investigation BACKGROUND: Increased plasma plasminogen activator inhibitor-1 (PAI-1) activity and decreased tissue plasminogen activator (tPA) activity could be considered a true component of the metabolic syndrome (MetS) associated with an increased risk of developing cardiovascular diseases (CVD) and fibrinolytic abnormalities. The aim of this study was to investigate the association of tPA and its inhibitor PAI-1 with type 2 diabetes (T2D) and MetS and interrelationship between PAI-1and tPA activities and antigens in Malaysian T2D and normal subjects. METHODS: The plasma activities and antigens of PAI-1 and tPA and the levels of the tPA/PAI-1 complex as well as serum insulin, parameter of the coronary risk panel and plasma glucose at fasting state were studied in 303 T2D subjects (227 with MetS and 76 without MetS), 131 normal non-diabetic non-metabolic subjects and 101 non-diabetic MetS subjects. RESULTS: The PAI-1 activity was higher in subjects with T2D with MetS (P = 9.8 × 10(-19)) and non-diabetic subjects with MetS (P = 3.0 × 10(-15)), whereas the tPA activity was lower in T2D with MetS (P = 0.003) as compare to normal subjects. Plasma tPA antigen levels were higher in subjects with T2D with MetS (P = 8.9 × 10(-24)), T2D without MetS (P = 1.3 × 10(-13)) and non-diabetic MetS subjects (P = 0.002). The activity and antigen of PAI-1 in normal subjects were related to insulin resistance (P = 2.2 × 10(-4); 0.007). Additionally, the PAI-1 activity was associated with an increased waist circumference (P = 2.2 × 10(-4)) and decreased HDL-c (P = 0.005), whereas the tPA activity was associated with decreased FBG (P = 0.028). The highest correlation was between PAI-1 activity and its antigen (R(2 )= 0.695, P = 1.1 × 10(-36)) in diabetic subjects. The tPA activity negatively correlated with its antigen (R(2 )= -0.444, P = 7.7 × 10(-13)) in normal subjects and with the PAI-1 activity and antigen (R(2 )= -0.319, P = 9.9 × 10(-12); R2 = -0.228, P = 3.4 × 10(-6)) in diabetic subjects. CONCLUSIONS: PAI-1 and tPA activities and antigens were associated with diabetes and MetS parameters in Malaysian subjects. BioMed Central 2011-03-18 /pmc/articles/PMC3064636/ /pubmed/21414238 http://dx.doi.org/10.1186/1475-2840-10-23 Text en Copyright ©2011 Al-Hamodi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Investigation
Al-Hamodi, Zaid
Ismail, Ikram S
Saif-Ali, Riyadh
Ahmed, Khaled A
Muniandy, Sekaran
Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
title Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
title_full Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
title_fullStr Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
title_full_unstemmed Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
title_short Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
title_sort association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in malaysian subjects
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064636/
https://www.ncbi.nlm.nih.gov/pubmed/21414238
http://dx.doi.org/10.1186/1475-2840-10-23
work_keys_str_mv AT alhamodizaid associationofplasminogenactivatorinhibitor1andtissueplasminogenactivatorwithtype2diabetesandmetabolicsyndromeinmalaysiansubjects
AT ismailikrams associationofplasminogenactivatorinhibitor1andtissueplasminogenactivatorwithtype2diabetesandmetabolicsyndromeinmalaysiansubjects
AT saifaliriyadh associationofplasminogenactivatorinhibitor1andtissueplasminogenactivatorwithtype2diabetesandmetabolicsyndromeinmalaysiansubjects
AT ahmedkhaleda associationofplasminogenactivatorinhibitor1andtissueplasminogenactivatorwithtype2diabetesandmetabolicsyndromeinmalaysiansubjects
AT muniandysekaran associationofplasminogenactivatorinhibitor1andtissueplasminogenactivatorwithtype2diabetesandmetabolicsyndromeinmalaysiansubjects